A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

Introduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Thus, this study aimed to examine the effectiveness and saf...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ludan Zhang, Rui Ge, Deng Pan, Pengjie Yue, Jingwen Zhang, Renjie Bian, Xiaojing Yan
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2024-05-01
סדרה:	Frontiers in Pharmacology
נושאים:	myelodysplastic syndromes chronic myelomonocytic leukemia venetoclax hypomethylating agents real-world study
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1265840/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!